Clinical Trials Using Erlotinib Hydrochloride

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Erlotinib Hydrochloride. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 31
1 2 Next >

  • Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

    This randomized phase III trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 1265 locations

  • Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

    This randomized phase II-R / III trial studies gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that was removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, capecitabine, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells. Giving chemotherapy together with or without erlotinib hydrochloride and / or radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether chemotherapy is more effective when given with or without erlotinib hydrochloride and / or radiation therapy in treating pancreatic cancer.
    Location: 660 locations

  • Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients with Stage III Non-small Cell Lung Cancer

    This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, etoposide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving erlotinib hydrochloride is more effective than crizotinib with chemoradiation therapy in treating patients with non-small cell lung cancer.
    Location: 169 locations

  • Maintenance Chemotherapy with or without Stereotactic Body Radiation Therapy in Treating Patients with Stage IV Non-small Cell Lung Cancer

    This randomized phase II trial studies how well giving maintenance chemotherapy with or without stereotactic body radiation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving maintenance chemotherapy and stereotactic body radiation therapy together may work better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer.
    Location: 66 locations

  • My Pathway: A Study Evaluating Herceptin / Perjeta, Tarceva, Zelboraf / Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

    This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and / or are not suitable options per the treating physician's judgment.
    Location: 17 locations

  • A Phase 1 / 1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors

    This is a Phase 1 / 1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 in subjects with advanced solid tumors.
    Location: 9 locations

  • Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

    Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival. To exploit the dependence of tumors on glutamine, CB-839, a potent and selective inhibitor of the first enzyme in glutamine utilization, glutaminase, will be tested in this Phase 1 study in patients with solid tumors. This study is an open-label Phase 1 evaluation of CB-839 in patients with advanced solid tumors. The study will be conducted in 2 parts. Part 1 is a dose escalation study enrolling patients with locally-advanced, metastatic and / or refractory solid tumors to receive CB-839 capsules orally twice or three times daily. In Part 2, patients with each of the following diseases will be enrolled: A) Triple-Negative Breast Cancer, B) Non-Small Cell Lung Cancer (adenocarcinoma), C) Renal Cell Cancer, D) Mesothelioma, E) Fumarate hydratase (FH)-deficient tumors, F) Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST), G) SDH-deficient non-GIST tumors, H) tumors harboring mutations in isocitrate dehydrogenase-1 (IDH1) or IDH2, and I) cMyc mutation tumors. As an extension of Parts 1 & 2, patients will be treated with CB-839 in combination with standard chemotherapy. Combination groups include: Pac-CB, CBE, CB-Erl, CBD, and CB-Cabo. Pac-CB: patients with locally-advanced or metastatic TNBC will be treated with paclitaxel and CB-839. CBE: patients with advanced clear cell RCC or papillary RCC will be treated with everolimus in combination with CB-839. CB-Erl: patients with advanced NSCLC lacking the T790M EGFR mutation will be treated with erlotinib and CB-839. CBD: patients with NSCLC harboring KRAS mutation will be treated with docetaxel and CB-839. CB-Cabo: patients with histologically confirmed diagnosis of locally-advanced, inoperable or metastatic RCC treated with cabozantinib in combination with CB-839. All patients will be assessed for safety, pharmacokinetics (plasma concentration of drug), pharmacodynamics (inhibition of glutaminase), biomarkers (biochemical markers that may predict responsiveness in later studies), and tumor response.
    Location: 10 locations

  • Trametinib and Erlotinib Hydrochloride in Treating Patients with Stage IV or Recurrent Lung Cancer with EGFR Activating Mutation

    This phase I / II trial studies the side effects of trametinib when given together with erlotinib hydrochloride and to see how well they work in treating patients with lung cancer that has an EGFR activating mutation and is stage IV or has come back. Trametinib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 6 locations

  • Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients with Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

    This phase I / II trial studies the side effects and best dose of onalespib lactate when given together with erlotinib hydrochloride and to see how well they work in treating patients with EGFR-mutant non-small cell lung cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Erlotinib hydrochloride and onalespib lactate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 6 locations

  • Local Therapy and Erlotinib Hydrochloride in Treating Patients with Oligometastatic, EGFR-Mutant Non-small Cell Lung Cancer

    This pilot clinical trial studies how well local therapy (including surgical removal, ablation [using heat to destroy the tumor], or radiation therapy) and erlotinib hydrochloride work in treating patients with non-small cell lung cancer that has spread to more than one place in the body (oligometastatic) but less than five, and that has a mutation in the EGFR gene. Local therapy may help destroy the cancer in the places it has spread. Erlotinib hydrochloride may stop the growth of tumor cells by blocking the EGFR protein, which may help stop cancer cell growth. Using local therapy in combination with erlotinib hydrochloride may be a better treatment for oligometastatic, EGFR-mutant lung cancer.
    Location: 6 locations

  • Erlotinib Hydrochloride in Treating Patients with Bladder Cancer Undergoing Surgery

    This randomized phase II trial studies how well erlotinib hydrochloride works in treating patients with bladder cancer undergoing surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 6 locations

  • A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

    The purpose of this study is to determine whether nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.
    Location: 5 locations

  • Rapid Blood Test in Detecting EGFR Mutation for Early Initiation of Erlotinib Hydrochloride in Treating Patients with Advanced Lung Cancer

    This phase II trial studies how well a rapid blood test works in detecting the EGFR mutation and how well early initiation of erlotinib hydrochloride works in treating patients with lung cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Detecting tumor cells in the blood stream and performing genetic analysis may be a faster way to select patients for treatment. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Starting erlotinib hydrochloride early may be a better way to treat patients with EGFR mutant lung cancer.
    Location: 4 locations

  • A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced / Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

    The purpose of this study is to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of INC280 in combination with erlotinib in the Phase Ib of this study, and to assess the anti-tumor activity and safety of INC280 alone, and in combination with erlotinib, versus platinum with pemetrexed in the Phase II of this study, in adult patients with EGFR mutated, cMET amplified, advanced / metastatic non-small cell lung cancer with acquired resistance to prior EGFR TKI.
    Location: 5 locations

  • A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

    A Phase I / 2 multi-center open-label study of BGB324 in combination with erlotinib in patients with Stage IIIb or Stage IV non-small cell lung cancer. BGB324 is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is connected with poor prognosis and acquired resistance to therapy.
    Location: 5 locations

  • TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
    Location: 4 locations

  • A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC

    The main purpose of this study is to evaluate the safety and efficacy of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in participants with stage IV non small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Del19 and L858R). Safety and tolerability of ramucirumab in combination with erlotinib will be assessed in the first portion (Part A) before proceeding to the second portion of this study (Part B).
    Location: 3 locations

  • Capmatinib and Erlotinib Hydrochloride in Treating Patients with Previously Treated Non-small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of capmatinib and erlotinib hydrochloride when given together in treating patients with previously treated non-small cell lung cancer. Capmatinib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Erlotinib Hydrochloride before Surgery in Treating Patients with Stage III Non-Small Cell Lung Cancer

    This phase II trial studies how well erlotinib hydrochloride works before surgery in treating patients with stage III non-small cell lung cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: 3 locations

  • Bevacizumab and Erlotinib Hydrochloride in Treating Patients with Hereditary Leiomyomatosis and Advanced Kidney Cancer

    This phase II trial studies how well bevacizumab and erlotinib hydrochloride work in treating patients with hereditary leiomyomatosis and kidney cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Bevacizumab binds to a protein called vascular endothelial growth factor (VEGF) and may prevent the growth of new blood vessels that tumors need to grow. Erlotinib hydrochloride may stop the growth of tumor cells by blocking a protein called epidermal growth factor receptor (EGFR) that is needed for cell growth. Giving bevacizumab and erlotinib hydrochloride may be an effective treatment for hereditary leiomyomatosis and kidney cancer.
    Location: 2 locations

  • Ixazomib Citrate and Erlotinib Hydrochloride in Treating Patients with Advanced, Metastatic, Relapsed, or Refractory Solid Tumors

    This phase I trial studies the side effects and best dose of ixazomib citrate when given together with erlotinib hydrochloride in treating patients with solid tumors that have spread to other places in the body, has come back, or does not respond to treatment. Ixazomib citrate and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Erlotinib Hydrochloride and Temozolomide in Treating Younger Patients with Relapsed, Recurrent, or Refractory Solid Tumors

    This phase II trial studies how well erlotinib hydrochloride (erlotinib) and temozolomide work in treating younger patients with solid tumors that have returned after a period of improvement or do not respond to treatment. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving temozolomide and erlotinib hydrochloride may work better in treating patients with solid tumors.
    Location: Washington University School of Medicine, Saint Louis, Missouri

  • Gemcitabine Hydrochloride and Erlotinib Hydrochloride as Second Line Therapy in Treating Patients with Locally Recurrent or Metastatic Pancreatic Cancer That Cannot Be Removed by Surgery

    This phase I trial studies the side effects and the best dose of erlotinib hydrochloride when given together with gemcitabine hydrochloride as second line therapy in treating patients with pancreatic cancer that cannot be removed by surgery that has spread from where it started to nearby tissue or lymph nodes or that has spread to other parts of the body. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving erlotinib hydrochloride with gemcitabine hydrochloride may be a better treatment for pancreatic cancer.
    Location: University of California San Diego, San Diego, California

  • Cisplatin or Carboplatin and Docetaxel with or without Erlotinib Hydrochloride in Treating Patients with Stage III-IVB Oral Cavity Cancer That Can Be Removed by Surgery

    This randomized phase II trial studies how well cisplatin or carboplatin and docetaxel with or without erlotinib hydrochloride works in treating patients with stage III-IVB mouth (oral cavity) cancer that can be removed by surgery. Drugs used in chemotherapy, such as cisplatin, carboplatin, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective with or without erlotinib hydrochloride in treating oral cavity cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Binimetinib and Erlotinib Hydrochloride in Treating Patients with Stage IV Non-small Cell Lung Cancer

    This phase I / IB trial studies the side effects and best dose of binimetinib when given together with erlotinib hydrochloride in treating patients with stage IV non-small cell lung cancer. Binimetinib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Moffitt Cancer Center, Tampa, Florida


1 2 Next >